Quotient (NASDAQ:QTNT) major shareholder Life Sciences Maste Perceptive bought 450,000 shares of the stock in a transaction on Wednesday, May 23rd. The shares were acquired at an average price of $6.45 per share, with a total value of $2,902,500.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Quotient stock opened at $6.80 on Friday. The stock has a market cap of $305.90 million, a PE ratio of -2.25 and a beta of -0.02. The company has a debt-to-equity ratio of 22.54, a current ratio of 2.34 and a quick ratio of 1.65. Quotient has a one year low of $2.78 and a one year high of $7.73.
Several analysts have weighed in on QTNT shares. ValuEngine lowered shares of Quotient from a “sell” rating to a “strong sell” rating in a research note on Friday, May 18th. BidaskClub upgraded shares of Quotient from a “hold” rating to a “buy” rating in a research note on Friday, March 16th. Zacks Investment Research lowered shares of Quotient from a “hold” rating to a “sell” rating in a research note on Wednesday, April 4th. Finally, BTIG Research set a $10.00 target price on shares of Quotient and gave the company a “buy” rating in a research note on Sunday, May 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $11.50.
Institutional investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company grew its position in shares of Quotient by 341.8% during the first quarter. The Manufacturers Life Insurance Company now owns 21,820 shares of the company’s stock worth $103,000 after acquiring an additional 16,881 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Quotient by 1,722.9% during the fourth quarter. Wells Fargo & Company MN now owns 33,961 shares of the company’s stock worth $168,000 after acquiring an additional 32,098 shares during the last quarter. Deutsche Bank AG grew its position in shares of Quotient by 65.7% during the fourth quarter. Deutsche Bank AG now owns 59,686 shares of the company’s stock worth $294,000 after acquiring an additional 23,670 shares during the last quarter. Opaleye Management Inc. bought a new position in shares of Quotient during the first quarter worth about $282,000. Finally, Lombard Odier Asset Management USA Corp bought a new position in shares of Quotient during the fourth quarter worth about $751,000. Institutional investors and hedge funds own 61.55% of the company’s stock.
Quotient Company Profile
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.